Leerink Swann maintains an 'Outperform' on Idenix Pharmaceuticals (IDIX); Clinical Hold Feels More Like Precaution

Article Stock Quotes (3) Comments (0)

Leerink Swann maintains an 'Outperform' on Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) price target of $13.00.

Analyst, Howard Liang, said, "While the FDA's partial hold on IDX184 could potentially delay IDIX's IFN-free combination trial initially planned by YE:12 and likely puts any partnership discussions on hold, we believe it likely reflects the structural resemblance between IDX184 and BMS'094 (INX-189, BMY) Bristol Myer (NYSE: BMY), resulting in an identical active metabolite. We believe that after the sell-off yesterday there is little valuation in the stock for IDX184 or other pipeline agents, as our NPV analysis suggests that probability-weighted potential royalties from GILD's GS-7977 (Nasdaq: GILD) (as a result of ongoing patent interference proceedings) would support IDIX's current market cap."

For an analyst ratings summary and ratings history on Idenix Pharmaceuticals Inc. click here. For more ratings news on Idenix Pharmaceuticals Inc. click here.

Shares of Idenix Pharmaceuticals Inc. closed at $5.84 yesterday, with a 52 week range of $4.30-$15.25.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Analyst Sees Potential for Omeros' (OMER) OMS824 as FDA Gives Clearance
• Imperial Capital Boosts Price Target on Dick's (DKS); 'Best-of-Breed'
• Pandora (P) Posts 'Strong Quarter' - Needham & Company

Create E-mail Alert Related Categories

Analyst Comments, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?